(Q35559229)

English

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).

scientific article published on 24 April 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

mucopolysaccharidosis II

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Arian Pano

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ann J Barbier

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Bonnie Bielefeld

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

David A H Whiteman

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

David A Amato

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

24 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Orphanet Journal of Rare Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

copyright license

Creative Commons Attribution 4.0 International

24 April 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Enzyme replacement therapy for lysosomal storage diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Sonographic biometry of liver and spleen size in childhood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

27 July 2018

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

26 September 2018

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

26 September 2018

Initial report from the Hunter Outcome Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416269

26 September 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1186%2FS13023-015-0265-2

21 January 2018

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

1 reference

https://api.crossref.org/works/10.1186%2FS13023-015-0265-2

21 January 2018

Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25902842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/25902842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13023-015-0265-2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35559229&oldid=2197478959"